MedTrace Logo

Promus PREMIER Below The Knee Registry

NCT05054764 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-09-23

No results posted yet for this study

Summary

The Promus Premier below-the-knee (BTK) drug-eluting stent (DES) is specifically designed to improve BTK vessel patency rates using a platinum-chromium alloy based stent that elutes the anti-restenotic drug everolimus to inhibit neo-intimal hyperplasia. Although DES stents are considered standard of care for certain BTK lesions, there is a paucity of data on the use of DES in the contemporary BTK chronic limb threatening ischemia (CLTI) population, especially in Singapore. The aim of the Promus PREMIER BTK registry is to collect one year data of the Boston Scientific Promus PREMIER BTK DES in BTK lesions in CLTI patients.

Conditions

  • Peripheral Arterial Disease
  • Arterial Disease
  • Arterial Disease of Legs

Interventions

DEVICE

Promus PREMIER BTK DES

Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients

Sponsors & Collaborators

  • Sengkang General Hospital

    lead OTHER

Principal Investigators

  • Jia Sheng Tay · Sengkang General Hospital

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2023-02-28
Completion
2023-08-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054764 on ClinicalTrials.gov